share_log

Tonix Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Tonix Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Tonix Pharmaceuticals | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/13 06:14

Moomoo AI 已提取核心訊息

Tonix Pharmaceuticals reported Q3 2024 financial results with net revenue of $2.8 million and a net loss of $14.2 million, compared to revenue of $4.0 million and a net loss of $28.0 million in Q3 2023. Research and development expenses decreased 57% to $9.1 million, while selling, general and administrative expenses declined 11% to $7.7 million. The company recorded $1.7 million in grant income during the quarter.The company's cash position stood at $28.2 million as of September 30, 2024. During Q3, Tonix raised approximately $41.8 million through ATM offerings and an additional $3.5 million through a securities purchase agreement. The company expects current cash resources to fund operations into Q1 2025 but will require additional financing to continue operations beyond that point.Tonix's lead program TNX-102 SL for fibromyalgia received FDA Fast Track designation in Q3 2024, with an NDA submitted in October 2024. The company expects an FDA decision on NDA acceptance and PDUFA date in December 2024. Additionally, Tonix secured a DTRA contract worth up to $34 million over five years to develop TNX-4200, a broad-spectrum antiviral agent targeting CD45.
Tonix Pharmaceuticals reported Q3 2024 financial results with net revenue of $2.8 million and a net loss of $14.2 million, compared to revenue of $4.0 million and a net loss of $28.0 million in Q3 2023. Research and development expenses decreased 57% to $9.1 million, while selling, general and administrative expenses declined 11% to $7.7 million. The company recorded $1.7 million in grant income during the quarter.The company's cash position stood at $28.2 million as of September 30, 2024. During Q3, Tonix raised approximately $41.8 million through ATM offerings and an additional $3.5 million through a securities purchase agreement. The company expects current cash resources to fund operations into Q1 2025 but will require additional financing to continue operations beyond that point.Tonix's lead program TNX-102 SL for fibromyalgia received FDA Fast Track designation in Q3 2024, with an NDA submitted in October 2024. The company expects an FDA decision on NDA acceptance and PDUFA date in December 2024. Additionally, Tonix secured a DTRA contract worth up to $34 million over five years to develop TNX-4200, a broad-spectrum antiviral agent targeting CD45.
Tonix Pharmaceuticals報告了2024年第三季度的財務結果，淨營業收入爲280萬美元，淨虧損爲1420萬美元，而2023年第三季度的營業收入爲400萬美元，淨虧損爲2800萬美元。研究和開發費用減少了57%，降至910萬美元，而銷售、一般和行政費用下降了11%，降至770萬美元。公司在本季度記錄了170萬美元的贈款收入。截至2024年9月30日，公司現金狀況爲2820萬美元。在第三季度，Tonix通過ATm發行籌集了大約4180萬美元，並通過證券購買協議額外籌集了350萬美元。公司預計目前的現金資源將支持到2025年第一季度，但在那之後將需要額外的融資以繼續運營。Tonix的...展開全部
Tonix Pharmaceuticals報告了2024年第三季度的財務結果，淨營業收入爲280萬美元，淨虧損爲1420萬美元，而2023年第三季度的營業收入爲400萬美元，淨虧損爲2800萬美元。研究和開發費用減少了57%，降至910萬美元，而銷售、一般和行政費用下降了11%，降至770萬美元。公司在本季度記錄了170萬美元的贈款收入。截至2024年9月30日，公司現金狀況爲2820萬美元。在第三季度，Tonix通過ATm發行籌集了大約4180萬美元，並通過證券購買協議額外籌集了350萬美元。公司預計目前的現金資源將支持到2025年第一季度，但在那之後將需要額外的融資以繼續運營。Tonix的主導項目TNX-102 SL用於纖維肌痛症在2024年第三季度獲得FDA快速通道認證，提交了NDA於2024年10月。公司預計FDA將在2024年12月對NDA接受情況及PDUFA日期作出決定。此外，Tonix獲得了一份DTRA合同，價值高達3400萬美元，爲期五年，用於開發TNX-4200，這是一種針對CD45的廣譜抗病毒藥物。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    科技巨頭財報季如火如荼，英偉達壓軸會表現如何？
    週四， $亞馬遜 (AMZN.US)$ 該公司報告第四季度調整後每股收益爲1.86美元，高於1.50美元的預期，營業收入爲1877.9亿美元，高於1873.2亿美元的預期。公司預測下一季度營收將低於華爾街的預期，預計本季度最多爲1550亿美元，而分析師們希望達到1580亿美元。 展开
    亞馬遜收益預覽：通過猜測開盤價格獲得獎勵！